Actively Recruiting
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
Led by University of Rochester · Updated on 2025-07-09
114
Participants Needed
1
Research Sites
288 weeks
Total Duration
On this page
Sponsors
U
University of Rochester
Lead Sponsor
S
Stanford University
Collaborating Sponsor
AI-Summary
What this Trial Is About
A recently completed study suggested that processing speed and attention (PS/A) oriented cognitive training (VSOP) produced robust effect on PS/A and working memory, but not in cognitive control or episodic memory, and long-term effects were overall modest. The proposed R01 renewal proposes to identify additional attributes to further enhance transferred and long-term effects of PS/A training in older adults with amnestic mild cognitive impairment (MCI) by addressing adaptation capacity that underpins adaptive learning and neuroplasticity. The goal of the stage II double-blinded randomized trial is to test whether adding resonance frequency breathing (RFB) training to VSOP will strengthen multiple contributors to adaptation capacity, particularly the central and peripheral pathways of autonomic nervous system (ANS) flexibility, which will strengthen VSOP training effect on cognitive and brain function and slow the progress of dementia in MCI. The central hypothesis is that strengthening adaptation capacity, via improving autonomic nervous system (ANS) flexibility, will enhance neuroplasticity and slow progress of dementia in MCI, since adaptation capacity is critical for neuroplasticity of VSOP, but compromised in neurodegenerative process. Older adults with MCI (n = 114) will be randomly assigned to an 8-week combined intervention (RFB+VSOP), VSOP with guided imagery relaxation (IR) control, and a waitlist IR control, with periodical booster training sessions at follow-ups. Mechanistic and distal outcomes include ANS flexibility and multiple markers of dementia progress. Data will be collected across a 14-month period. The two primary aims are to examine long-term effects of the combined intervention on ANS flexibility (Aim 1), as well as the cognitive, behavioral, and functional capacity (Aim 2). The exploratory aim will be to determine the preliminary long-term effect of the combined intervention on neurodegeneration. This can be a reasonable renewal plan from the completed study, aiming to identify additional attributes to further enhance transferred and long-term effects of cognitive training in MCI. This will be among the first randomized controlled trials to examine a novel, combined intervention targeting adaptation capacity in MCI, with an ultimate goal for slowing neurodegeneration. In addition, research on how to monitor adherence - the extent to which VSOP training is delivered and followed as intended - has been conceptually and methodologically limited. Robust monitoring of adherence to cognitive training requires valid assessment of effective engagement. Here, we apply our well-supported, novel framework of mental fatigability for measuring effective engagement in cognitive training. Mental fatigability, the failure to remain engaged in tasks requiring sustained mental effort, can be captured via measures of self-reported disengagement, increase in reaction time during tasks, and facial expression of negative valence/low arousal. These markers of disengagement relate to ventromedial prefrontal cortex dysfunction. We will apply this framework to advance understanding of the underpinnings of adherence to VSOP training by monitoring the extent of effective engagement while using the training platform.
CONDITIONS
Official Title
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with mild cognitive impairment due to Alzheimer's disease using NIA and Alzheimer's Association criteria
- Memory complaint present
- Rey Auditory Verbal Learning Test delayed recall score less than 6
- Montreal Cognitive Assessment score between 18 and 25
- Activities of Daily Living Questionnaire score of 30 or less
- Intact capacity to consent as measured by the San Diego Brief Assessment of Capacity to Consent (UBACC)
- Stable dose of Alzheimer's disease medication, antidepressants, anxiolytics, or vascular-related medications for at least 3 months before recruitment
- Age between 60 and 89 years
- English speaking
- Adequate vision and hearing for mobile app use and testing by self-report
- Living in the community
You will not qualify if you...
- Currently enrolled in another cognitive improvement study
- Uncontrollable symptoms of major depression
- Major cerebrovascular or cardiovascular diseases (e.g., congestive heart failure, pacemaker, prior myocardial infarction)
- Neurological diseases such as Parkinson's disease or Multiple Sclerosis
- Having an active legal guardian indicating impaired decision-making capacity
- Contraindications to MRI (e.g., pacemaker, claustrophobia)
- Color blindness
- Alcohol dependency in the past 5 years that contributed to mild cognitive impairment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Feng Lin
Rochester, New York, United States, 14642-0001
Actively Recruiting
Research Team
F
Feng Lin, PhD
CONTACT
K
Kathi Heffner, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here